PL368556A1 - Sposoby leczenia albo zapobiegania chorobom skóryprzy zastosowaniu czynników wiążących CD2 - Google Patents

Sposoby leczenia albo zapobiegania chorobom skóryprzy zastosowaniu czynników wiążących CD2

Info

Publication number
PL368556A1
PL368556A1 PL02368556A PL36855602A PL368556A1 PL 368556 A1 PL368556 A1 PL 368556A1 PL 02368556 A PL02368556 A PL 02368556A PL 36855602 A PL36855602 A PL 36855602A PL 368556 A1 PL368556 A1 PL 368556A1
Authority
PL
Poland
Prior art keywords
treating
methods
binding agents
skin disorders
preventing skin
Prior art date
Application number
PL02368556A
Other languages
English (en)
Inventor
Akshay K. Vaishnaw
Kevin D. Cooper
Daniel Shrager
Thomas S. Mccormick
Original Assignee
Biogen, Inc.
University Hospital Of Cleveland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Inc., University Hospital Of Cleveland filed Critical Biogen, Inc.
Publication of PL368556A1 publication Critical patent/PL368556A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2824—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD58
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL02368556A 2001-02-01 2002-01-25 Sposoby leczenia albo zapobiegania chorobom skóryprzy zastosowaniu czynników wiążących CD2 PL368556A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26596401P 2001-02-01 2001-02-01

Publications (1)

Publication Number Publication Date
PL368556A1 true PL368556A1 (pl) 2005-04-04

Family

ID=23012611

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02368556A PL368556A1 (pl) 2001-02-01 2002-01-25 Sposoby leczenia albo zapobiegania chorobom skóryprzy zastosowaniu czynników wiążących CD2

Country Status (22)

Country Link
US (3) US20040170635A1 (pl)
EP (1) EP1409015A4 (pl)
JP (1) JP2004527477A (pl)
KR (1) KR20040043112A (pl)
CN (1) CN1527723A (pl)
AR (1) AR035079A1 (pl)
BG (1) BG108020A (pl)
BR (1) BR0206905A (pl)
CA (1) CA2436411A1 (pl)
CZ (1) CZ20032081A3 (pl)
EA (1) EA200300849A1 (pl)
EE (1) EE200300366A (pl)
GE (1) GEP20063828B (pl)
HU (1) HUP0303826A2 (pl)
IS (1) IS6894A (pl)
MX (1) MXPA03006919A (pl)
NO (1) NO20033443L (pl)
PL (1) PL368556A1 (pl)
SK (1) SK9722003A3 (pl)
WO (1) WO2002060480A1 (pl)
YU (1) YU61203A (pl)
ZA (1) ZA200305936B (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6764681B2 (en) 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
DE69927831T2 (de) * 1998-08-31 2006-07-20 Biogen, Inc., Cambridge Modulierung von gedächtnis-effector- zellen unter verwendung eines cd2-bindungsagens
WO2002098370A2 (en) * 2001-03-02 2002-12-12 Medimmune, Inc. Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
WO2003009740A2 (en) 2001-07-24 2003-02-06 Biogen Idec Ma Inc. Methods for treating or preventing sclerotic disorders using cd2-binding agents
SI1556020T1 (sl) 2002-08-12 2009-08-31 Birkir Sveinsson Uporaba spojin, ki so antagonisti CGRP, za zdravljenje psoriaze
US11517612B2 (en) 2016-11-18 2022-12-06 Nepsone Ehf Methods of treating inflammatory skin disorders
GB0307864D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
WO2005077018A2 (en) * 2004-02-06 2005-08-25 Astellas Us Llc Methods of treating skin disorders
KR20070011558A (ko) * 2004-05-04 2007-01-24 제네상스 파머슈티컬스, 아이엔씨. 일배체형 마커 및 치료에 대한 반응을 측정하기 위해 이를이용하는 방법
CA2565259A1 (en) 2004-05-07 2005-12-08 Astellas Us Llc Soluble lfa-3 polypeptide for treating viral disorders
US20060078580A1 (en) * 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
CN101113459A (zh) * 2007-07-16 2008-01-30 东莞太力生物工程有限公司 一种重组复制缺陷型病毒、含有该病毒的药物组合物及其应用
WO2011031676A2 (en) 2009-09-10 2011-03-17 Mayo Foundation For Medical Education And Research Depleting immunosuppressive monocytes within a mammal
WO2011059926A2 (en) 2009-11-10 2011-05-19 Mayo Foundation For Medical Eduction And Research Methods and materials for treating renal cell carcinoma
WO2014025198A2 (ko) * 2012-08-09 2014-02-13 주식회사 한독 Lfa3 변이체 및 상기 변이체 또는 lfa3 cd2 결합영역과 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도
WO2014078272A1 (en) 2012-11-13 2014-05-22 Mayo Foundation For Medical Education And Research Methods and materials for assessing immune system profiles
US10094835B2 (en) 2013-05-09 2018-10-09 Mayo Foundation For Medical Education And Research Treating patients based on immune subtypes
CA3094756A1 (en) * 2018-03-29 2019-10-03 Pfizer Inc. Lfa3 variants and compositions and uses thereof
JP2025517363A (ja) * 2022-05-17 2025-06-05 ザ ユーエービー リサーチ ファンデーション 炎症性皮膚障害を治療または予防するための方法及び組成物
WO2024050455A2 (en) * 2022-08-31 2024-03-07 Heitmeyer Jamie Nicole Anti-rhd antibodies for treating inflammatory dermal condition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU677772B2 (en) * 1991-10-07 1997-05-08 Biogen Idec Ma Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA -3 interaction
US6764681B2 (en) * 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US6162432A (en) * 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US5817311A (en) * 1993-03-05 1998-10-06 Universite Catholique De Louvain Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
US5730979A (en) * 1993-03-05 1998-03-24 Universite Catholique Delouvain LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation
US5951983A (en) * 1993-03-05 1999-09-14 Universite Catholique De Louvain Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies
DE69927831T2 (de) * 1998-08-31 2006-07-20 Biogen, Inc., Cambridge Modulierung von gedächtnis-effector- zellen unter verwendung eines cd2-bindungsagens

Also Published As

Publication number Publication date
CZ20032081A3 (cs) 2004-01-14
ZA200305936B (en) 2005-01-26
US20070031443A1 (en) 2007-02-08
GEP20063828B (en) 2006-05-10
YU61203A (sh) 2006-05-25
HUP0303826A2 (hu) 2004-03-01
WO2002060480A1 (en) 2002-08-08
JP2004527477A (ja) 2004-09-09
KR20040043112A (ko) 2004-05-22
EA200300849A1 (ru) 2004-02-26
AR035079A1 (es) 2004-04-14
NO20033443L (no) 2003-09-30
CN1527723A (zh) 2004-09-08
SK9722003A3 (en) 2004-05-04
MXPA03006919A (es) 2004-06-02
CA2436411A1 (en) 2002-08-08
WO2002060480A9 (en) 2004-05-27
BR0206905A (pt) 2004-07-06
US20040170635A1 (en) 2004-09-02
BG108020A (bg) 2004-03-31
US20030185824A1 (en) 2003-10-02
IS6894A (is) 2003-07-25
NO20033443D0 (no) 2003-08-01
EP1409015A1 (en) 2004-04-21
EP1409015A4 (en) 2006-04-12
EE200300366A (et) 2003-12-15

Similar Documents

Publication Publication Date Title
EP1328186A4 (en) METHODS OF TREATING VARIOUS EYES DISEASES
IL161327A0 (en) Methods for treating ocular neovascular diseases
AU2003286567A8 (en) Methods for the treatment of skin disorders
GB0007193D0 (en) Treatment of movrmrnt disorders
EP1446087A4 (en) METHOD FOR TREATING NON-NEUROPATHIC PAIN
IL172418A0 (en) Therapeutic agents useful for treating pain
EP1476147A4 (en) METHODS OF TREATING VIEW DISORDERS
GB0129976D0 (en) Treatment method
IL157592A0 (en) Carbamate compounds for use in preventing or treating movement disorders
EP1465968A4 (en) METHODS OF TREATING DISTILLATE DEODORIZER
IL157591A0 (en) Carbamate compounds for use in preventing or treating neurodegenerative disorders
MXPA03008582A (es) Agentes y metodos para tratamiento de cancer.
GB0108671D0 (en) Skin treatment
EP1419236A4 (en) METHODS OF TREATING OR PREVENTING SCLEROSIS BY USE OF CD2-BINDING AGENTS
IL157588A0 (en) Carbamate compounds for use in preventing or treating psychotic disorders
IL151891A0 (en) Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
GB0120147D0 (en) Treatment method
IL162053A0 (en) Method for the treatment of bone disorders
GB0130763D0 (en) Treatment methods
EP1425020A4 (en) METHOD AND COMPOSITIONS FOR TREATING APOPTOSIS-RELATED DISEASES
HK1064050A (en) Methods for treating or preventing skin disorders using cd2-binding agents
GB2397018B (en) Combination therapy for treating disease
AU2002342188A8 (en) Methods and compositions for treating flavivirus-mediated disease
GB2378387B (en) Apparatus for beauty treatment
GB0126253D0 (en) Treatment method

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)